BLA 103158 · Interferon Sciences
Alferon N Injection
Interferon Alfa-N3
NovelLast checked: Nov 20, 2026Latest source record: Oct 10, 1989 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1989
Oct 10, 1989
Approved uses
1
Original approval plus efficacy supplements
Registered trials
21
4 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 10, 1989 Original approval · Type 1 - New Molecular Entity
1 products under this application
- ALFERON N INJECTION · INTERFERON ALFA-N3 5MIU/VIAL · VIAL, · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Interferon Alfa-N3" as an intervention, any sponsor and status, largest first.
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00000844 · 560 participants
Drug: Interferon alfa-n3; Interferon alfa-n1 · For: HIV Infections
Sites: Los Angeles, California; Redwood City, California; New Haven, Connecticut · 15 sites in all
- Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00708500 · 404 participants · Start Aug 2008 · Primary completion Apr 2010
Drug: Boceprevir (SCH 503034); Pegylated interferon alfa-2b (SCH 54031) and 2 more · For: Hepatitis C, Chronic
- Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis CPivotal-lookingCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT00088504 · 315 participants · Start Jul 2004
Drug: Merimepodib; PEG-Interferon-alpha 2a (Pegasys®) and 1 more · For: Hepatitis C; Hepatitis
Sites: Birmingham, Alabama; Huntsville, Alabama; Phoenix, Arizona · 67 sites in all
- Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV InfectionPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT01482767 · 262 participants · Start Apr 2012 · Primary completion Apr 2015
Drug: Pegylated-Interferon Alfa 2b (PEG-IFN); Ribavirin (RBV) and 1 more · For: HIV Infections; Hepatitis C
Sites: Birmingham, Alabama; Los Angeles, California; Palo Alto, California · 43 sites in all
- Boceprevir/PegIFN α-2b/Riba in HCV+ Gt1 Menopausal Women, Nonresponders to PegIFN/Riba or Treatment-naives (MEN_BOC)Pivotal-lookingStatus unknown
University of Modena and Reggio EmiliaAcademic, hospital or other
NCT01457937 · 240 participants (planned) · Start Nov 2011 · Primary completion Dec 2013
Drug: Pegylated Interferon, Ribavirin, Boceprevir · For: Chronic Hepatitis C; Menopause
Sites: Modena, Italy
ANRS, Emerging Infectious DiseasesGovernment (non-federal)
NCT01335529 · 69 participants · Start May 2011 · Primary completion May 2014
Drug: Boceprevir, Peg-interferon alfa 2b and Ribavirin · For: HCV Coinfection; HIV-1 Infection
Sites: Marseille, France
National Cancer Institute (NCI)NIH
NCT00026143 · 60 participants · Start Oct 2001 · Primary completion Jul 2004
Drug: recombinant interleukin-12; recombinant interferon alfa · For: Recurrent Melanoma; Stage IV Melanoma
Sites: Chicago, Illinois
Interferon SciencesIndustry
NCT00002018 · 60 participants
Drug: Interferon alfa-n3 · For: HIV Infections
Sites: New York, New York
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Management of condylomata acuminata with Alferon N injection, interferon alfa-n3 (human leukocyte derived).
Friedman-Kien A · Am J Obstet Gynecol 1995 · Clinical Trial, Multicenter Study
- Neuropsychological effects of Interferon Alfa-n3 treatment in asymptomatic human immunodeficiency virus-1-infected individuals.
Mapou RL, Law WA, Wagner K, et al. · J Neuropsychiatry Clin Neurosci 1996 · Clinical Trial, Clinical Trial, Phase I
- Adjuvant interferon for anal condyloma. A prospective, randomized trial.
Fleshner PR, Freilich MI · Dis Colon Rectum 1994 · Clinical Trial, Controlled Clinical Trial
- Phase I trial of interferon alfa-n3 in early-stage human immunodeficiency virus type 1 disease: evidence for drug safety, tolerance, and antiviral activity.
Skillman DR, Malone JL, Decker CF, et al. · J Infect Dis 1996 · Clinical Trial, Clinical Trial, Phase I
- Extravascular administration of interferon alfa-N3 increases serum exposure and 2-5(A) synthetase activity.
Sturgill MG, Rashidbaigi A, Liao MJ, et al. · J Clin Pharmacol 2000 · Clinical Trial, Randomized Controlled Trial
- Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial.
Sostegni R, Ghisetti V, Pittaluga F, et al. · Hepatology 1998 · Clinical Trial, Randomized Controlled Trial
Sponsor: Interferon Sciences
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.